PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50325F80014Oseltamivir phosphate 75mg capsules (ndc — Exelan Pharmaceuticals Inc

Exelan Pharmaceuticals Inc holds $184.3M across 125 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 5 related awards under parent 36F79720D0227. Competition previously drew 3 offers. Recompete timing centers on the Jun 29, 2027 PoP end — agencies typically plan 12–18 months ahead.

Aspr/Orm-Sns
Awarding office
Exelan Pharmaceuticals Inc
Recipient
Jun 29, 2027
PoP end
$74.1M
Obligated
325412
NAICS
6505
PSC
3 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Federal
Contract number75A50325F80014
Also listed as36F79720D0227-75A50325F80014
AgencyAspr/Orm-Sns
Awarding officeAspr/Orm-Sns
IncumbentExelan Pharmaceuticals Inc
UEIFYZXNHSQTMG8
NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDV36F79720D0227
Place of performanceBOCA RATON, FL
Related solicitation75A50325Q00001
PoP end (current)Jun 29, 2027
Obligated$74.1M

OSELTAMIVIR PHOSPHATE 75MG CAPSULES (NDC: 76282-0704-45); 10 CT. BLISTERS PACKS AND OSELTAMIVIR PHOSPHATE 30MG CAPSULES… is a federal award for Aspr/Orm-Sns held by Exelan Pharmaceuticals Inc. Estimated value $74.1M ($74.1M obligated). Current period of performance ends Jun 29, 2027. Last award drew 3 bidders. Place of performance: BOCA RATON, FL. Related solicitation 75A50325Q00001.

OSELTAMIVIR PHOSPHATE 75MG CAPSULES (NDC: 76282-0704-45); 10 CT. BLISTERS PACKS AND OSELTAMIVIR PHOSPHATE 30MG CAPSULES (NDC: 76282-0702-45); 10 CT. BLISTERS PACKS.

Recompete timing

Public
● Expiring in 272 days

Current PoP ends Jun 29, 2027 (272 days remaining). Agencies typically plan 12–18 months ahead — at 8.9 months out, that window is already open. The buying decision is likely already in motion.

Bonuses end Sept 30

Want the durability read on 75A50325F80014? One Pursuit Analysis, $500, inside 48 business hours.

  • 48 business hours
  • $500
  • Credits toward the Pack
Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Exelan Pharmaceuticals Inc — $184.3M obligated across 125 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).

% of firm-wide obligated ($184.3M) · all agencies
Department of Veterans Affairs (VA)$110.2M · 60%Department of Health and Human Services (HHS)$74.1M · 40%Department of Justice (DOJ)$39K · 0%
Open full company profile →

Related awards

Same parent · incumbent
36C24726F0053
LENALIDOMIDE CAPSULES
Department of Veterans Affairs (VA) · EXELAN PHARMACEUTICALS INC.
$4.8M
Dec 7, 2026
36C24626N0410
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
Department of Veterans Affairs (VA) · EXELAN PHARMACEUTICALS INC.
$5.1M
Jan 14, 2027
36C24626N0416
LENALIDOMIDE FOR THE DURHAM VAMC FOR PATIENT CARE
Department of Veterans Affairs (VA) · EXELAN PHARMACEUTICALS INC.
$4.5M
Jan 14, 2027
36C24626N0420
LENALIDOMIDE FOR THE RICHMOND VAMC FOR PATIENT CARE
Department of Veterans Affairs (VA) · EXELAN PHARMACEUTICALS INC.
$4.1M
Jan 14, 2027
36C24626N0422
LENALIDOMIDE FOR FAYETTEVILLE VAMC PATIENT CARE
Department of Veterans Affairs (VA) · EXELAN PHARMACEUTICALS INC.
$3.5M
Jan 14, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract 75A50325F80014?

75A50325F80014 (Oseltamivir phosphate 75mg capsules (ndc) is a Aspr/Orm-Sns award with an estimated value of $74.1M, currently held by Exelan Pharmaceuticals Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50325F80014?

Aspr/Orm-Sns awarded 75A50325F80014 to Exelan Pharmaceuticals Inc.

Who is the incumbent on 75A50325F80014?

Exelan Pharmaceuticals Inc is the incumbent with $184.3M across 125 related awards in SCOUT’s public footprint. The current period of performance ends Jun 29, 2027.

When does Exelan Pharmaceuticals Inc’s 75A50325F80014 come up for recompete?

SCOUT tracks a period-of-performance end of Jun 29, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 75A50325F80014? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75A50325F80014